Activation of the JAK-STAT pathway by olanzapine is necessary for desensitization of serotonin2A receptor-stimulated phospholipase C signaling in rat frontal cortex but not serotonin2A receptor-stimulated hormone release
Restricted accessOtherFirst published online July, 2010
Activation of the JAK-STAT pathway by olanzapine is necessary for desensitization of serotonin2A receptor-stimulated phospholipase C signaling in rat frontal cortex but not serotonin2A receptor-stimulated hormone release
Chronic treatment with olanzapine causes desensitization of serotonin 2A receptor signaling. The purpose of the current study was to further understand the mechanisms underlying this desensitization response of serotonin 2A receptor signaling in vivo. We report that desensitization of serotonin 2A receptor stimulated-phospholipase C activity in rat frontal cortex induced by olanzapine is dependent on the activation of the JAK-STAT pathway. Olanzapine treatment for 7 days significantly increased the levels of the regulator of G protein signaling (RGS7) protein, RGS7 mRNA levels, and activation of JAK2 in rat frontal cortex. Pre-treatment with a JAK2 inhibitor AG490, significantly attenuated the olanzapine-induced reductions in serotonin 2A receptor—stimulated phospholipase C activity and prevented the olanzapine-induced increases in RGS7 mRNA and protein levels. In contrast, inhibition of the JAK-STAT pathway with AG490 did not reverse the olanzapine-induced desensitization of the serotonin 2A receptor pathway in the hypothalamic paraventricular nucleus mediating increases in plasma hormone levels. AG490 dose-dependently inhibited serotonin 2A receptor—stimulated oxytocin and corticosterone release. These results suggest that the olanzapine-induced increase in RGS7 expression is mediated by the activation of JAK-STAT and is necessary for olanzapine-induced desensitization of serotonin 2A receptor—stimulated phospholipase C activity in the frontal cortex but not serotonin 2A receptor—stimulated hormone release.
Arranz, MJ, Collier, DA, Munro, J., Sham, P., Kirov, G., Sodhi, M., et al. (1996) Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett217: 177-178.
2.
Banes, AK, Shaw, SM, Tawfik, A., Patel, BP, Ogbi, S., Fulton, D., et al. (2005) Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin. Am J Physiol Cell Physiol288: C805-C812.
3.
Benzing, T., Kottgen, M., Johnson, M., Schermer, B., Zentgraf, H., Walz, G., et al. (2002) Interaction of 14-3-3 protein with regulator of G protein signaling 7 is dynamically regulated by tumor necrosis factor-alpha . J Biol Chem277: 32954-32962.
4.
Benzing, T., Yaffe, MB, Arnould, T., Sellin, L., Schermer, B., Schilling, B., et al. (2000) 14-3-3 interacts with regulator of G protein signaling proteins and modulates their activity. J Biol Chem275: 28167- 28172.
5.
Blackshear, MA, Sanders-Bush, E. ( 1982) Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exp Ther221: 303-308.
6.
Burysek, L., Syrovets, T., Simmet, T. ( 2002) The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways. J Biol Chem277: 33509-33517.
7.
Cattaneo, E., Conti, L., De-Fraja, C. ( 1999) Signalling through the JAK-STAT pathway in the developing brain. Trends Neurosci22: 365-369.
8.
Cohrs, S., Roher, C., Jordan, W., Meier, A., Huether, G., Wuttke, W., et al. (2006) The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl) 185: 11-18.
9.
Damjanoska, KJ, Heidenreich, BA, Kindel, GH, D’Souza, DN, Zhang, Y., Garcia, F., et al. (2004) Agonist-induced serotonin 2A receptor desensitization in the rat frontal cortex and hypothalamus. J Pharmacol Exp Ther309: 1043-1050.
10.
Damjanoska, KJ, Van de Kar, LD, Kindel, GH, Zhang, Y., D’Souza, DN, Garcia, F., et al. (2003) Chronic fluoxetine differentially affects 5-hydroxytryptamine (2A) receptor signaling in frontal cortex, oxytocin- and corticotropin-releasing factor-containing neurons in rat paraventricular nucleus . J Pharmacol Exp Ther306: 563-571.
11.
Dohlman, HG, Thorner, J. ( 1997) RGS proteins and signaling by heterotrimeric G proteins . J Biol Chem272: 3871-3874.
12.
D’Souza, DN, Zhang, Y., Damjanoska, KJ, Carrasco, GA, Sullivan, NR, Garcia, F., et al. (2004) Estrogen reduces serotonin-1A receptor-mediated oxytocin release and Galpha(i/o/z) proteins in the hypothalamus of ovariectomized rats. Neuroendocrinology80: 31-41.
13.
Fuller, RW, Snoddy, HD ( 1984) Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats. Characterization by the use of antagonists. Neuropharmacology23: 1389-1394.
14.
Fumagalli, F., Frasca, A., Sparta, M., Drago, F., Racagni, G., Riva, MA ( 2006) Long-term exposure to the atypical antipsychotic olanzapine differently up-regulates extracellular signal-regulated kinases 1 and 2 phosphorylation in subcellular compartments of rat prefrontal cortex. Mol Pharmacol69: 1366-1372.
15.
Goyer, PF, Berridge, MS, Morris, ED, Semple, WE, Compton-Toth, BA, Schulz, SC, et al. (1996) PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med37: 1122-1127.
16.
Gray, JA, Roth, BL ( 2001) Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull56: 441-451.
17.
Guillet-Deniau, I., Burnol, AF, Girard, J. ( 1997) Identification and localization of a skeletal muscle secrotonin 5-HT2A receptor coupled to the Jak/STAT pathway. J Biol Chem272: 14825-14829.
18.
Guo, D., Dunbar, JD, Yang, CH, Pfeffer, LM, Donner, DB ( 1998) Induction of Jak/STAT signaling by activation of the type 1 TNF receptor. J Immunol160: 2742-2750.
19.
Gu, Z., Jiang, Q., Yan, Z. ( 2007) RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia. Mol Pharmacol71: 1030-1039.
20.
Hanley, NR, Hensler, JG ( 2002) Mechanisms of ligand-induced desensitization of the 5-hydroxytryptamine(2A) receptor. J Pharmacol Exp Ther300: 468-477.
21.
Hatzimanolis, J., Lykouras, L., Markianos, M., Oulis, P. ( 1998) Neuro-chemical variables in schizophrenic patients during switching from neuroleptics to clozapine. Prog Neuropsychopharmacol Biol Psychiatry22: 1077-1085.
Li, Q., Levy, AD, Cabrera, TM, Brownfield, MS, Battaglia, G., Van de Kar, LD ( 1993) Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT1A agonist, 8-OH-DPAT, in male rats . Brain Res630: 148-156.
24.
Lu, XH, Bradley, RJ, Dwyer, DS ( 2004) Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res1011: 58-68.
25.
Markianos, M., Hatzimanolis, J., Lykouras, L. ( 2001) Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone. Psychopharmacology ( Berl) 157: 55-59.
26.
Masellis, M., Basile, V., Meltzer, HY, Lieberman, JA, Sevy, S., Macciardi, FM, et al. (1998) Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology19: 123-132.
27.
Mirnics, K., Middleton, FA, Stanwood, GD, Lewis, DA, Lewir, P. ( 2001) Diease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry6: 293-301.
28.
Muma, NA, Singh, RK, Vercillo, MS, D’Souza, DN, Zemaitaitis, B., Garcia, F., et al. (2007) Chronic olanzapine activates the Stat3 signal transduction pathway and alters expression of components of the 5-HT2A receptor signaling system in rat frontal cortex. Neuropharmacology53: 552-562.
29.
Naughton, M., Mulrooney, JB, Leonard, BE ( 2000) A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol15: 397-415.
30.
Nichols, DE, Frescas, S., Marona-Lewicka, D., Huang, X., Roth, BL, Gudelsky, GA, et al. (1994) 1-(2,5-Dimethoxy-4-(trifluoromethyl) phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist. J Med Chem37: 4346-4351.
31.
Roth, BL, Berry, SA, Kroeze, WK, Willins, DL, Kristiansen, K. ( 1998) Serotonin 5-HT2A receptors: molecular biology and mechanisms of regulation. Crit Rev Neurobiol12: 319-338.
32.
Roth, BL, Sheffler, DJ, Kroeze, WK ( 2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov3: 353-359.
33.
Scheepers, FE, Gespen de Wied, CC, Kahn, RS ( 2001) The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia. J Clin Psychopharmacol21: 575-582.
34.
Shirayama, Y., Hashimoto, K., Suzuki, Y., Higuchi, T. ( 2002) Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr Res58: 69-74.
35.
Singh, RK, Shi, J., Zemaitaitis, BW, Muma, NA ( 2007) Olanzapine increases RGS7 protein expression via stimulation of the Janus tyrosine kinase-signal transducer and activator of transcription signaling cascade. J Pharmacol Exp Ther322: 133-140.
36.
Singh, RK, Dai, Y., Staudinger, JL, Muma, NA (2009) Activation of the JAK-STAT pathway is necessary for desensitization of 5HT2A receptor-stimulated phospholipase C signaling by Olanzapine, Clozapine and MDL100907. Int J Neuropsychopharmacol12: 651-655.
37.
Tepavcevic, D., Giljevic, Z., Korsic, M., Halimi, S., Suchanek, E., Jelic, T., et al. (1994) Effects of ritanserin, a novel serotonin-S2 receptor antagonist, on the secretion of pituitary hormones in normal humans 2. J Endocrinol Invest17: 1-5.
38.
Tuomisto, J., Mannisto, P. ( 1985) Neurotransmitter regulation of anterior pituitary hormones . Pharmacol Rev37: 249-332.
39.
Walker, EF, Bonsall, R., Walder, DJ ( 2002) Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis 1. Neuropsychiatry Neuropsychol Behav Neurol15: 10-17.
40.
Wilcox, CS, Aminoff, MJ, Millar, JG, Keenan, J., Kremer, M. ( 1975) Circulating levels of corticotrophin and cortisol after infusions of L-DOPA, dopamine and noradrenaline, in man. Clin Endocrinol (Oxf) 4: 191-198.
41.
Xu, X., Zeng, W., Popov, S., Berman, DM, Davignon, I., Yu, K., et al. (1999) RGS proteins determine signaling specificity of Gq-coupled receptors. J Biol Chem274: 3549-3556.
42.
Yu, YW, Tsai, SJ, Yang, KH, Lin, CH, Chen, MC, Hong, CJ ( 2001) Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine. Neuropsychobiology43: 79-82.
43.
Zhang, JH, Simonds, WF ( 2000) Copurification of brain G-protein beta5 with RGS6 and RGS7. J Neurosci20: RC59.
44.
Zhang, W., Bymaster, FP ( 1999) The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology ( Berl) 141: 267-278.
45.
Zhang, Y., Damjanoska, KJ, Carrasco, GA, Dudas, B., D’Souza, DN, Tetzlaff, J., et al. (2002) Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI. J Neurosci22: 9635-9642.
